Article

Plasma cell myeloma with RAS/BRAF mutations: Clinicopathologic, molecular genetic features and outcomes of 68 patients

2022-07-28

Abstract excerpt

<title>Abstract</title> <p>High-throughput genomic analysis of plasma cell myeloma has identified recurrent gene mutations of prognostic significance. Mutations in the RAS-MAPK pathway, such as <italic>KRAS</italic>, <italic>NRAS</italic>, and <italic>BRAF</italic>, are known as high-risk factors associated with poor prognosis in patients with various types of cancers, but studies in myeloma have yielded mixed re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6d357131-27db-5854-9bcd-99c46f174b0f
DOI: 10.21203/rs.3.rs-1879409/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Plasma cell myeloma with RAS/BRAF mutations: Clinicopathologic, molecular genetic features and outcomes of 68 patientsDOI 10.21203/rs.3.rs-1879409/v1Read

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.Semantic proximity Read

Circulating plasma cells (either polyclonal or monoclonal) as markers of aggressive Multiple Myeloma phenotypeSemantic proximity Read

Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity Read

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Semantic proximity Read

Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.Semantic proximity Read

Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technologySemantic proximity Read

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.Semantic proximity Read

RAS/RAF landscape in monoclonal plasma cell conditions.Semantic proximity Read

Clinical presentation and treatment of plasmablastic myeloma-a multicenter retrospective analysisSemantic proximity Read

Multiple Myeloma Genomics – A Concise ReviewSemantic proximity Read

Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working GroupSemantic proximity Read

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.Semantic proximity Read